Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570908 · ClinicalTrials.gov registry record · Phase 2
Brain Mets - Capecitabine Plus Sunitinib and WBRT
A Phase 2 study, sponsored by Baylor Breast Care Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00570908 is a Phase 2 study that was terminated before completion, run by Baylor Breast Care Center. The registered enrollment target is 12 participants.
The verdict
NCT00570908, a Phase 2 study, was terminated before completion, sponsored by Baylor Breast Care Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of concurrent whole brain radiotherapy (WBRT) and capecitabine followed by combination capecitabine and sunitinib in treating patients with CNS metastases from breast cancer.
Interventions
- DRUG capecitabine
- DRUG sunitinib
- RADIATION WBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570908
The ClinicalTrials.gov registry entry for NCT00570908 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Breast Care Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which capecitabine is the first listed.
NCT00570908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00570908 about?
NCT00570908 is a clinical study titled "Brain Mets - Capecitabine Plus Sunitinib and WBRT". The purpose of this study is to assess the efficacy and safety of concurrent whole brain radiotherapy (WBRT) and capecitabine followed by combination capecitabine and sunitinib in treating patients with CNS metastases from breast cancer.
What is the current status of trial NCT00570908?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2009-02. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00570908?
The interventions under investigation include: capecitabine (DRUG), sunitinib (DRUG), WBRT (RADIATION).
Who is sponsoring clinical trial NCT00570908?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.